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Methods A cost-effectiveness analysis was carried out for photodynamic therapy (PDT)
performed in early stage lung cancer cases, which by definition have no lymph node meta-
stasis. The alternative treatment method was lobectomy, which conventionally would have
been the first choice of treatment. Costs (C) and effectiveness (E) both of the PDT group
and operation group were compared. Effectiveness was determined using quality adjusted
life years saved (QALYs) which is the 5-year survival rate adjusted in terms of the quality
of life of the patient, and the cost-effectiveness rate was obtained based on the costs of
treatment methods during the patient’s stay in the hospital. Health care costs, including
drugs, were calculated according to the 1992 National Health Insurance list in yen. Costs
which were non-reimbursable by the public insurance system, such as for special rooms and
sun block cream, were also expressed in yen.
Results The total cost of the operated group was 1,793,832 and that for the PDT
group was 1,017,104. The cost-effectiveness rate of the operated group, that is the
average cost of treatment per postoperative living month, was 37,537, while that of
the entire PDT group was 30,003. This indicates that the cost-effectiveness rate for the
operated group is apparently 1.3 times higher than that of the PDT group. The monthly
cost-effectiveness rate for the PDT group of lesions smaller than 2cm was 25,533.
Therefore the cost in the operated group is 1.5 times higher.
Conclusions This study demonstrated the merits of PDT for early stage lung cancer
from the point of view of cost-effectiveness.
Keywords: Photodynamic therapy, Lung cancer, Cost-effectiveness
Abbreviations." QALYs, quality adjusted life years saved; PDT, photodynamic therapy
Corresponding author. Tel.: 813-3342-6111, ext. 5071. Fax: 813-3349-0326.10 H. KATO et al.
INTRODUCTION
Lung cancer remains the leading cause of cancer
death in most Western countries. Despite thousands
ofclinical trials, the introduction ofnew approaches
to management, and improvements in supportive
care, the outlook for most patients diagnosed with
carcinoma of the lung remains poor. The rising
demand for health care services coupled with static
or decreasing resources with which to pay for them
has resulted in increasing interest in the economic
analysis of medical interventions [1-3]. In this
situation, the merits of new cancer therapy are
now compared not only in terms of effectiveness
but also cost of treatment.
Photodynamic therapy (PDT), a relatively new
modality used in the treatment ofcancer, has gained
considerable acceptance in the past decade [4,5]. A
wide variety of malignancies have been treated by
this method and according to literature, over 3000
patients worldwide have been treated with PDT [6].
In Japan, PDT with photofrin and excimer dye laser
obtained government approval in October 1995 and
finally obtained national insurance reimbursement
status in April 1996 [7].
This article analyzes the cost-effectiveness in
Japan of the new cancer treatment method, PDT,
for early stage lung cancer.
MATERIALS AND METHODS
Estimate of Costs
The following basic assumptions were made:
(1) Disease: early stage lung cancer (TisNOM0) [8].
(2) Treatment method: curative lobectomy orPDT.
In cases of surgery, resection of only one lobe.
(3) Period ofhospital stay: 40 days for the operation
group (including 3 days in the intensive care
unit), 14 days for the PDT group.
(4) No combined chemotherapy or radiotherapy.
(5) Complete curability must be obtained with one
surgery procedure or one session of PDT. No
recurrence.
(6) Costs of treatment for accompanying diseases
are not included in the study.
The standard regimen was established based on
the above assumptions, and costs of treatment were
obtained by adding the various costs. In this study,
the costs estimated include only remuneration costs
and other costs paid by the patients during hospital
stay and do not include costs after discharge.
Because of the typically high age of the subjects,
many cases had other diseases such as gastric ulcer
and high blood pressure, and treatment for such
accompanying diseases was often performed simul-
taneously. However, such costs were excluded from
this study. Total costs can be expressed as follows:
C C1 + C2 + C3 + C4 + C5 + C6 + C7 + C8,
where
C cost of medication,
C2 cost of injections,
C3 cost of examination,
C4 cost of diagnostic imaging,
C5 cost of treatment,
C6 cost of surgery and anesthesia,
C7 cost of diagnosis and hospital stay, and
C8 cost for special (individual) rooms.
Costs C1-C7 are all reimbursable by the public
health insurance and C8 must be covered by the
patient.
Costs C1-C8 for the operation group (operated)
and the PDT group were estimated as follows.
Lobectomy was performed in the operated group
and PDT was performed in the PDT group. Since
the comparison of costs was made at the point
of 5-year survival, in 1993, costs were computed
according to the 1992 Ministry of Health and
Welfare guidelines [9,10].
(1) C1 cost ofmedication
The prices of drugs used and cost of compounding
are shown in Table I. Based on accumulated data,
the average overall cost of drug administration was
calculated to be 20,000. The PDT group was
assumed to receive 30cc of 4% xylocaine on the
day of treatment, 30cc of 4% xylocaine, 3 tablets
of antibiotic preparation per day and 3 tablets ofCOST-EFFECTIVENESS OF PDT IN LUNG CANCER 11
TABLE Cost of medication (in yen)
Operated group PDT group
Basic prescription fee 420 Basic prescription fee 420
Prescription fee 930 Prescription fee 150
Antibiotics, analgesics, antipyretic, 18,650 Topical anesthesia 980
anti-inflammatory, Antibiotics 1310
anti-bronchoconstrictor, Anti-inflammatory 320
laxative, etc. Sun block cream 1000
Total 20,000 Total 4180
TABLE II Cost of injections (in yen)
Operated group PDT group
i.v., i.m. injection
Antibiotics(2 types), diuretics,
bronchial mucolytics, blood substitute,
analgesics, antiallergics, cholinergic blocker,
parasympathomimetics, etc.
i.v. drip injection
Antibiotics(2 types), bronchial mucolytics, blood substitute,
H2 receptor antagonist, eupeptic agent, electrolyte transfusion,
blood plasma substitute, steroid, extracorporeal circulation
diluent, gastric acid inhibitor, diuretics, antihypertensives,
antiulcerative, antiallergics, hemostatics, etc.
i.v. drip route (930 4)
Total
20,000
i.v., i.m. injection
Porfimer sodium 427,000
Glucose fluid 130
Atropine sulfate 100
i.v. drip injection 290
120,000 Electrolyte fluid
3720 i.v. drip route 930
143,720 Total 428,450
analgesic anti-inflammatory per day for 3 days on
which follow-up bronchoscopy was performed, and
sun block cream. Since sun block cream is not an
NHI listed drug, the price for an over-the-counter
sun block cream was used.
(2) C2---cost ofdrug injection (Table II)
The cost of drug injection consists of costs for the
intravenous (i.v.) injection, subcutaneous injection
and i.v. drip injection. The cost of i.v. drip injection
constitutes a large part of the costs of the operated
group. It was assumed that patients postoperatively
receive a combination of two types of antibiotic
preparations; blood substitute; electrolytic transfu-
sion; liver disease, allergies and antiulcer drugs;
6 times i.v. drip injection or intravenous injection,
and the costs for other drugs were added. Calcula-
tion for thePDT group was based on their receiving
porfimer sodium, and 500ml electrolyte transfu-
sion to maintain i.v. lines and one ampule of atro-
pine sulfate on the day of treatment. The price of
porfimer sodium was 427,000, established by The
Ministry of Health and Welfare.
(3) C3 cost ofexamination (Table III)
Patients in the operated group normally stay in the
intensive care unit (ICU) for 3 days after the
operation. The costs during this period are charged
as the ICU fee, and thus are not included in this
section. It is not necessary to perform thoracotomy
for any examination in the PDT group, but it
requires 3 bronchoscopy examinations, including
bronchial toilet procedures, the costs of which are
included here.
(4) C4- cost ofdiagnostic imaging (Table IV)
Fewer chest X-rays were required for the PDT
group.
(5) C5 cost oftreatment (Table V)
Since the cost of bronchial toilet after PDT is
included in C3, the cost of treatment for the PDT12 H. KATO et al.
TABLE III Cost of examination (in yen)
Operated group PDT group
Basic examination 52,000 18,200
Basic evaluation 9000 4500
Hematological
Routine examination 300 300
Peripheral blood data 350 350
Fibrinogen amount 1850 1850
Fibrinolytic products 1350 1350
Biochemical
Protein demarcation 350 350
Blood gas 6000 8000
Ferritin precision 2100 2100
Aldosterone 3000 3000
Renin 2150 2150
Biochemical evaluation 1100 1100
Immunological
HCV antibody 2500 2500
Pathological 46,100 20,100
Cardioputmonary 6100 5000
Monitoring after operation 11,570 0
Clearance test 4500 4500
Endoscopic
Bronchofiberscopy 15,000 15,000
Follow-up 27,000
Drug etc. 2680 8040
Total 168,000 125,390
TABLE IV Cost of diagnostic imaging (in yen)
Operated group PDT group
Roentgenography
Basic diagnostic fee 20,000 9800
Films 4380 1460
Lung tomography 5280 5280
Films 4890 4890
Bone scintigram 25,000 25,000
Diagnosis 3750 3750
Films, drugs 35,160 35,160
CT scan 10,450 10,450
Diagnosis 3750 3750
Films, drugs 22,400 22,400
Angiogram 13,050 0
Total 148,110 121,940
group here is 0. TableV shows the breakdown ofthe
treatment for the operated group. Placement of an
indwelling catheter, ultrasonic nebulizer, and oxy-
gen inhalation equipment during the patients’ stay
in the ICU is included in the ICU cost, thus the cost
TABLE V Cost of treatment (in yen)
Operated group PDT group
4050 Postoperative treatment of
the wound
Drainage 630
Oxygen inhalation 1950
Oxygen 3970
Indwelling catheter 500
Continuous gastric drainage 420
Tube 750
Intermittent positive pressure 1600
breathing
Drug, oxygen 70
Nebulizer drug 360
Ultrasonic nebulizer drugs 240
Local anesthesia during drain 70
placement
Total 14,610 0
TABLE VI Cost of surgery and anesthesia (in yen)
Operated group PDT group
Cost ofprocedure
Lobectomy 319,000
Automatic suture 27,000
Drugs 65,440
Cost of anesthesia
Closed circulatory systemic 91,000
anesthesia (5 h)
Epidermal anesthesia 7500
Continuous injection of 800
anesthesia
Subcutaneous arterial oxygen 1500
monitoring
Thoracic epidermal block 15,000
Drugs 1610
Total 528,850
87,000
87,000
of treatment for this group is limited to costs for
drugs, catheter and oxygen.
(6) C6 costofoperationandanesthesia (Table VI)
The cost ofoperation includes lobectomy, use ofone
automatic suture device, anesthesia, antibiotics, and
local hemostatic agents, etc. Concerning the anes-
thesia, it was assumed that closed circulatory sys-
temic anesthesia is performed for 5 h, in addition to
epidural anesthesia, monitoring of subcutaneous
arterial oxygen saturation and neural block.COST-EFFECTIVENESS OF PDT IN LUNG CANCER 13
It was decided to estimate the running cost of the
excimer dye laser and the technical charge. Assum-
ing that one excimer dye laser costs 40,000,000
and is used for 6 years, the annual depreciation
is 6,670,000. The running cost for year can be
obtained by adding the maintenance fee (routine
checkup fee, part exchange fee, janitorial fee, etc.) of
2,500,000, laser dye of 300,000, and laser gas of
200,000 to the above 6,670,000. Assuming that
50 patients will undergo this procedure per year,
the running cost for one patient is obtained by
dividing the running cost for one year by 50 plus
40,000 for the light transmission fiber and 1000
for electricity (234,400). Adding these up, the total
cost of the procedure is assumed to be 500,000. In
addition, since PDT only requires local anesthesia
for bronchofiberscopy, which is already included
in the examination category cost, the cost of local
anesthesia is not included in this section.
nursing care. Including the preoperative period, the
length of stay in the hospital was assumed to be 40
days for the operated group and 14 days for the
PDT group. However, the operated group has an
extra charge for stay in the ICU for 3 days, for
which time the cost of hospital stay (apart from
food costs) was excluded.
(8) C8 costfor special rooms
Special room costs differ greatly depending on
individual hospitals, and the number ofpatients per
room. This study applied the average extra cost for
special rooms of 4356 reported in the 1991 inves-
tigation ofroom cost by the Insurance Department
of the Ministry of Health and Welfare. This cost
cannot be obtained for stays in the ICU. C8 for the
operated group was 161,172 and that for the PDT
group was 60,984.
(7) C7=cost of diagnosis and hospital stay
(Table VII)
The cost of diagnosis for both operated and PDT
groups includes 1950 for initial examination and
5000 for management of the records of malignant
tumor treatment.
Concerning the costs related to hospital stay, it
was assumed that patients receive regular food, use
a regular bed and pajamas and receive high quality
RESULTS
Table VIII shows the total cost for the operated
group and the PDT group from C1 to C8. The total
cost of the operated group was 1,793,832 and that
for the PDT group was 1,017,104.
In this analysis the end point of the treatment
is set as 5-year survival and the cost-effectiveness
is estimated on a monthly basis. This study used
TABLE VII Cost of diagnosis and hospital stay (in yen)
Operated PDT
group group
Initial examination fee 2300 2300
Management of malignant 5000 5000
tumor treatment
Medical management fee
at the time of admission
Days 1-14 62,810 79,940
Addition for ICU 186,000
Days 15 up to month 59,200
1-2 months 25,800
Basic nursing fee 124,320 47,040
S-2 class nursing fee, days 1-30 56,430 29,260
days 31- 19,800
Room charge 67,710 25,620
Total 609,370 189,160
TABLE VIII Total cost of operated group and PDT group
(in yen)
Operated group PDT group
C cost ofmedication 20,000 4180
C2 cost of injections 143,720 428,450
C3 cost ofexamination 168,000 125,390
C4 cost of diagnostic 148,110 121,940
imaging
C5 cost of treatment 14,610 0
C6 cost of surgery and 528,850 87,000
anesthesia
C7 cost of diagnosis and 609,370 189,160
hospital stay
C8 cost for special rooms 161,172 60,984
Total 1,793,832 1,017,10414 H. KATO et al.
retrospective data from Tokyo Medical College.
The 5-year survival for the operated group (39 cases)
was 91% and that of the PDT (total 36 cases) group
was 95.1%. PDT cases with lesions under 2cm in
maximum dimension (30 cases) obtained a 5-year
survival rate of 100% [7,11]. Causes ofdeath for the
operated group include postoperative complica-
tions such as pneumonia, pyothorax, and infection.
The average survival was 54.6 months for the oper-
ated group, 51.06 months for the entire PDT group.
The quality of life of patients in the operated
group as measured by percent vital capacity (%VC)
decreased by 10%. Since no lobectomy was per-
formed in the PDT group, the %VC remained
at 100%. The quality of life was estimated in terms
of the quality of adjusted life years (QALYs). In
the post-procedural period of observation of 5
years QALYs of patients were 49.14 months for
the operated group, 51.06 months for the entire
PDT group and 60 months for PDT cases with
lesions less than 2cm in maximum dimension.
QALY units were used to indicate effectiveness in
this study.
Using the costs and effectiveness discussed above,
the rates ofcost-effectiveness ofthe two groups were
compared. The cost-effectiveness rate of the oper-
ated group, that is the average cost oftreatment per
postoperative living month, was 37,537, while that
ofthe entirePDT group was 30,003. This indicates
that the cost-effectiveness rate for the operated
group is apparently 1.3 times lower than that of
thePDT group. The monthly cost-effectiveness rate
for the PDT group of lesions smaller than 2cm was
25,533. Therefore the cost in the operated group is
1.5 times higher.
DISCUSSION
Increasing numbers of early stage lung cancer cases
are being detected as a result of improved survey
and diagnostic techniques. Despite the possibility
of curative resection in such cases, many patients
are frequently at high surgical risk because of
coexisting chronic obstructive pulmonary disease
or cardiovascular disease. Considering the quality
of life of the patients, it is essential to preserve lung
tissue by treating the initial early stage lung cancer
as conservatively as possible. The introduction of
PDT has provided a new therapeutic alternative to
surgery.
PDT aims to treat cancer through the photo-
chemical reaction of the drug which is specifi-
cally taken up by cancer cells by (1) intravenous
injection and (2) shining low-power laser photo-
radiation of the lesion. The authors began investi-
gation of these techniques in collaboration with
Dr. Thomas Dougherty in 1978 and demonstrated
their effectiveness in both diagnosis and treatment
in canine lung cancer models, and subsequently
applied these methods in clinical cases in 1980
[12,13]. Since then, 370 cases, including 240 lung
cancer patients (283 lesions), were treated with
PDT in our institution. There were several cases of
5-year survival, including the first such case in the
world treated by PDT alone [14].
PDT has no serious side effects apart from
sensitivity to sunlight. It was also apparent that it
not only reduces the psychological and physical
burden on patients but also is a therapy with high
economical cost-effectiveness in the Japanese medi-
cal environment. In addition, PDT has the advan-
tage ofnot excluding other therapeutic possibilities,
and even cases in which a satisfactory result was
not obtained with PDT can still subsequently
undergo surgery. PDT obtained a 100% 5-year
survival rate for early stage superficial squamous
cell carcinomas, with a maximum dimension of less
than 2 cm, indicating the possibility of taking the
place of surgery as the first treatment of choice
for cancer at this stage. At present the rate of
detection of lesions at such an early stage is very
low, but it is expected that the frequency ofdetection
will increase with the spread of sputum cytology
survey, thus improving the results of lung cancer
treatment.
This study attempted to evaluate and compare
PDT, a new lung cancer treatment method, with
conventional surgical operation in terms ofQALYs.COST-EFFECTIVENESS OF PDT IN LUNG CANCER 15
The data reflect the pattern ofcommon practice in
Japan. Both the PDT example and the example of
surgical treatment represent absolutely standard
approaches in Japan. This means that the periods
ofhospitalization for both procedures, as well as the
numbers and amounts ofconcomitantly used drugs
for the latter, are greater than in North America or
Europe. Effectiveness can be evaluated using the 5-
year survival rates for both therapeutic methods,
but the decrease of pulmonary function, especially
vital capacity after lobectomy, was also taken into
account. Resection of a part of the lung affects the
quality of postoperative life.
Lobectomy used to be performed for treatment of
tuberculosis, which resulted in longer survival time
for patients. However, cases which underwent
lobectomy showed subsequent decrease in pulmo-
nary function, requiring home oxygen therapy in
some cases. In addition, as a result of lowered
respiratory function, the risk of respiratory insuf-
ficiency due to infection becomes high. In the
treatment of cancer, lobectomy can cause similar
complications as in tuberculosis cases. Therefore, it
was decided to use the condition of the post-
operative pulmonary function (%VC) as an indica-
tion of quality of prognosis. If lobectomy is not
performed, the pulmonary function can be main-
tained at the preoperative level postoperatively
(%VC= 100%), but lobectomy in some extreme
cases can result in death. It was attempted to
evaluate the quality of life based on %VC.
Average lengths of survival were adjusted using
the rate ofdecrease in %VC as an index ofquality of
life, and this was used to indicate true effectiveness,
expressed in terms of QALYs. This is in principle
similar to Karnofsky’s performance status, in which
method QOL is indicated by the patient’s ability to
perform various activities [15]. In these analyses the
number of data is often limited and analysis is
restricted to some extent. Analysis of a long-term
model could be possible if data on multiple cancer,
rate of recurrence, rate of survival, etc. were
available.
Even in Japan, where its people have lived under
the protection and security of its health plan, the
country’s health budget is now in jeopardy. For
instance, in the treatment for cancer, there was a
great tendency to turn to surgery alone. However,
the current way of treatment emphasizes the
patient’s needs and QOL greatly while maintaining
cost-effectiveness. As a result ofthis "new" tendency,
the number ofminor invasive treatment cases, such
as PDT, bave been increasing. With the develop-
ment of second generation photosensitizers, which
produce no skin photosensitivity, patients treated
with PDT may now possibly be admitted for a
shortened term; thereby contributing to the cost
effectiveness of Japan’s health budget.
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